AI Employees for E-CommerceBeta

Unlock 24/7 fully automated AI staff for your online store. Experience the future of e-commerce operations—no humans required. Limited closed beta access!

Get Early Access →

SEC Form 10-K filed by Cosmos Health Inc.

4/15/25 4:36:30 PM ET

$COSM

Other Pharmaceuticals

Health Care

Get the next $COSM alert in real time by email

Unavailable

Get the next $COSM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COSM

Date	Price Target	Rating	Analyst

More analyst ratings

$COSM
Leadership Updates

Live Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain
4/16/25 12:45:15 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology
CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc
12/26/24 1:30:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded
11/21/23 9:00:00 AM ET
$COSM
Other Pharmaceuticals
Health Care

$COSM
Press Releases

Fastest customizable press release news feed in the world

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered solid results in Q1 2025, highlighted by a significant increase in gross profit and positive performance on both an Adjusted EBITDA and Adjusted Net Income basis, reflecting a
5/15/25 2:30:35 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp
5/7/25 2:30:10 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was not
5/6/25 1:40:33 PM ET
$COSM
Other Pharmaceuticals
Health Care

$COSM
Financials

Live finance-specific insights

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S
4/30/25 12:50:09 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si
1/21/25 3:00:00 PM ET
$COSM
Other Pharmaceuticals
Health Care
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone
11/12/24 12:01:41 PM ET
$COSM
Other Pharmaceuticals
Health Care

SEC Form 10-K filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for
$COSM

$COSM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

$COSM
Leadership Updates

Live Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

$COSM
Press Releases

Fastest customizable press release news feed in the world

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

$COSM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

$COSM
Financials

Live finance-specific insights

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM
SEC Filings

SEC Form 10-Q filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

SEC Form 10-K filed by Cosmos Health Inc.

$COSM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

SEC Form 10-K filed by Cosmos Health Inc.

Chat with this insight

Recent Analyst Ratings for $COSM

$COSM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

$COSM Leadership Updates

Live Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

$COSM Press Releases

Fastest customizable press release news feed in the world

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

$COSM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

$COSM Financials

Live finance-specific insights

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM SEC Filings

SEC Form 10-Q filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

SEC Form 10-K filed by Cosmos Health Inc.

$COSM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Siokas Grigorios bought $15,217 worth of shares (34,004 units at $0.45), increasing direct ownership by 0.56% to 6,158,884 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $62,800 worth of shares (141,825 units at $0.44), increasing direct ownership by 2% to 6,124,880 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (174,172 units at $0.47), increasing direct ownership by 3% to 5,983,055 units (SEC Form 4)

Recent Analyst Ratings for
$COSM

$COSM
Insider Trading

$COSM
Leadership Updates

$COSM
Press Releases

$COSM
Large Ownership Changes

$COSM
Financials

$COSM
SEC Filings

$COSM
Insider Purchases